Compliance Clock Starts Ticking Under Historic Modernization of Cosmetic Regulations Act
Companies have one year to comply with US FDA registration and product listing requirements under the Modernization of Cosmetic Regulations Act of 2022, part of the $1.7tr omnibus spending package signed by President Joe Biden on 29 December. Trade groups applauded the historic milestone and the legislation’s departure from previous proposals, including the elimination of user fees.
You may also be interested in...
FDA announces plans to make submission portal available in October for meeting registration deadlines for facilities and product listings under Modernization of Cosmetics Regulation Act. Guidance also provides more specifics on data that should be submitted to agency.
Cosmetic Ingredient Review’s expert panel issued an insufficient data announcement for two prostaglandin analogs at its June meeting in Washington. The group is reviewing the substances – related to the active ingredient in Allergan’s prescription drug Latisse for eyelash growth – after the US FDA indicated that they could be used lawfully in cosmetic products.
US Commissioner of food and drugs Robert Califf told the Senate Appropriations Agriculture, Rural Development, FDA and Related Agencies Subcommittee that FDA is requesting $5m for implementation of cosmetics modernization for FY2024 and will seek $40m to complete the process in coming years.